MedImmune is advancing a pipeline of promising candidates in the areas of infectious disease, oncology and immunology. We are also actively seeking new opportunities and technologies to add to this pipeline. To date, we have formed several collaboration and licensing agreements with companies whose technology or therapeutic targets are strategically positioned to augment our own research and development initiatives. Several of our current R&D collaborations are listed below.

Burnham Institute
Medarex, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
Seattle Genetics, Inc.
VasGene Therapeutics, Inc.
Xencor, Inc.

See also: Strategic Alliances

Information about MedImmune's R&D collaborations is updated on a quarterly basis, based on publicly available information. Although we make a good faith effort to keep this content as current as possible, we do not have a duty to update information posted on our web site, and we will not be liable for any failure to update such information.

Medarex, Inc.
In November 2004, MedImmune and Medarex, Inc. entered into a collaboration agreement to develop and commercialize antibodies for treatment of autoimmune diseases. The two antibodies currently being developed, MEDI-545 (formerly MDX-1103) and and MEDI-546 (formerly MDX-1333), are believed to target the interferon-alpha and the type 1 interferon receptor, respectively. Experimental data shows that the interferon-alpha and the type 1 interferon receptor may be involved with lupus disease activity.

Seattle Genetics, Inc.
MedImmune and Seattle Genetics, Inc. entered into a collaboration agreement in April 2005 for use of Seattle Genetics' antibody-drug conjugate (ADC) technology, which utilizes the targeting abilities of monoclonal antibodies with proprietary linker systems to deliver potent drug payloads to specific cells. Under the terms of the agreement, MedImmune has rights to utilize ADC technology with antibodies against a single tumor target and may opt to use ADC technology in a second proprietary antibody program.